in a multicenter analysis , the effect of low-dose cytosine arabinoside ( ara-c ) ( 10 mg/ m2q 12 h subcutaneously for a minimum of 15 days ) has been assessed in 13 patients with acute leukemia ( 10 myeloid-aml- , 3 lymphocytic-all- ) and 7 patients with dysmyelopoietic syndromes ( dmps ) , conditions classified as refractory anemia with an excess of blasts ( raeb ) .
C0023467
aml
C0024264
lymphocytic